Britain’s health technology assessor (HTA) is moving to recommend against funding Casgevy (exagamglogene autotemcel), the second such blow for people with sickl 15 March 2024
There is a ray of hope for sickle cell disease (SCD) patients in the UK, after the British health technology assessor re-opened its review into Oxbryta (voxelot 1 March 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.